These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33134364)

  • 1. Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD
    Chicoine A; Illing K; Vuong S; Pinto KR; Alcorn J; Cosford K
    Front Vet Sci; 2020; 7():583404. PubMed ID: 33134364
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic of two oral doses of a 1:20 THC:CBD
    Lyons C; McEwan K; Munn-Patterson M; Vuong S; Alcorn J; Chicoine A
    Front Vet Sci; 2024; 11():1352495. PubMed ID: 38585296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs.
    Vaughn D; Kulpa J; Paulionis L
    Front Vet Sci; 2020; 7():51. PubMed ID: 32118071
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
    Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
    JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of escalating cannabinoid doses in healthy cats.
    Kulpa JE; Paulionis LJ; Eglit GM; Vaughn DM
    J Feline Med Surg; 2021 Dec; 23(12):1162-1175. PubMed ID: 33769105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ
    Peters EN; MacNair L; Mosesova I; Christians U; Sempio C; Klawitter J; Land MH; Ware MA; Turcotte C; Bonn-Miller MO
    Eur J Clin Pharmacol; 2022 Feb; 78(2):259-265. PubMed ID: 34664109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Cannabidiol, Cannabidiolic Acid, Δ9-Tetrahydrocannabinol, Tetrahydrocannabinolic Acid and Related Metabolites in Canine Serum After Dosing With Three Oral Forms of Hemp Extract.
    Wakshlag JJ; Schwark WS; Deabold KA; Talsma BN; Cital S; Lyubimov A; Iqbal A; Zakharov A
    Front Vet Sci; 2020; 7():505. PubMed ID: 33102539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized, Triple-Blind, Comparator-Controlled Parallel Study Investigating the Pharmacokinetics of Cannabidiol and Tetrahydrocannabinol in a Novel Delivery System, Solutech, in Association with Cannabis Use History.
    Berl V; Hurd YL; Lipshutz BH; Roggen M; Mathur EJ; Evans M
    Cannabis Cannabinoid Res; 2022 Dec; 7(6):777-789. PubMed ID: 35787693
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacokinetics, Safety, and Tolerability of a Medicinal Cannabis Formulation in Patients with Chronic Non-cancer Pain on Long-Term High Dose Opioid Analgesia: A Pilot Study.
    Bonomo Y; Norman A; Collins L; O'Neill H; Galettis P; Trinca J; Strauss N; Martin J; Castle D
    Pain Ther; 2022 Mar; 11(1):171-189. PubMed ID: 34921662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy: Preliminary Results of the CARE-E Study.
    Huntsman RJ; Tang-Wai R; Alcorn J; Vuong S; Acton B; Corley S; Laprairie R; Lyon AW; Meier S; Mousseau DD; Newmeyer D; Prosser-Loose E; Seifert B; Tellez-Zenteno J; Huh L; Leung E; Major P
    Front Neurol; 2019; 10():716. PubMed ID: 31333569
    [No Abstract]   [Full Text] [Related]  

  • 11. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
    Karschner EL; Darwin WD; Goodwin RS; Wright S; Huestis MA
    Clin Chem; 2011 Jan; 57(1):66-75. PubMed ID: 21078841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders.
    Fernández-Trapero M; Pérez-Díaz C; Espejo-Porras F; de Lago E; Fernández-Ruiz J
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32054131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
    Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
    Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract.
    Nadulski T; Sporkert F; Schnelle M; Stadelmann AM; Roser P; Schefter T; Pragst F
    J Anal Toxicol; 2005; 29(8):782-9. PubMed ID: 16356335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.
    Atsmon J; Cherniakov I; Izgelov D; Hoffman A; Domb AJ; Deutsch L; Deutsch F; Heffetz D; Sacks H
    J Pharm Sci; 2018 May; 107(5):1423-1429. PubMed ID: 29287930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
    Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
    Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.
    Sholler DJ; Spindle TR; Cone EJ; Goffi E; Kuntz D; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
    J Anal Toxicol; 2022 May; 46(5):494-503. PubMed ID: 34089060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray.
    Stott CG; White L; Wright S; Wilbraham D; Guy GW
    Eur J Clin Pharmacol; 2013 May; 69(5):1135-47. PubMed ID: 23179176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of cannabichromene, cannabidiol, and Δ⁹-tetrahydrocannabinol and its metabolites in mouse brain following marijuana inhalation determined by high-performance liquid chromatography-tandem mass spectrometry.
    Poklis JL; Thompson CC; Long KA; Lichtman AH; Poklis A
    J Anal Toxicol; 2010 Oct; 34(8):516-20. PubMed ID: 21258613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.
    Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW
    Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.